Zymeworks (NASDAQ:ZYME) Reaches New 52-Week High – Here’s Why

Zymeworks Inc. (NASDAQ:ZYME)’s share price hit a new 52-week high on Tuesday . The stock traded as high as $29.95 and last traded at $29.5780, with a volume of 199051 shares trading hands. The stock had previously closed at $28.77.

Key Stories Impacting Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Jazz’s FDA approval covers Ziihera-based regimens for first-line treatment of adults with unresectable or metastatic HER2-positive GEA, including use regardless of PD-L1 status in certain patients. Phase 3 data showed median overall survival of more than two years, strengthening the commercial outlook for the therapy. Zymeworks FDA approval and milestone announcement
• Positive Sentiment: The approval triggers a $250 million milestone payment from Jazz, bringing total upfront and milestone payments from the partner to $650 million. Zymeworks also remains eligible for up to $1.3 billion in additional Jazz milestones and tiered royalties of 10% to 20% on net sales, plus potential payments and royalties from its BeOne collaboration. Zymeworks gains milestone from Jazz FDA approval
• Positive Sentiment: Analysts raised their valuation estimates: HC Wainwright increased its price target to $55 from $51 and maintained a Buy rating; Citigroup raised its target to $38 from $37 and also maintained Buy. Citizens JMP reaffirmed Market Outperform with a $32 target. Analyst target increases
• Neutral Sentiment: The FDA approval is supported by Phase 3 results, but the confirmatory trial remains ongoing and additional analyses are planned. Continued approval for an earlier biliary tract cancer indication may also depend on confirmatory evidence.
• Negative Sentiment: Zymeworks remains dependent on Jazz and BeOne for development, regulatory execution and commercialization. Delays, weaker-than-expected sales, unsuccessful confirmatory trials or safety concerns could reduce future milestone and royalty income.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ZYME. Deutsche Bank Aktiengesellschaft set a $32.00 price target on shares of Zymeworks in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a report on Friday, July 17th. Citigroup reissued a “market outperform” rating on shares of Zymeworks in a report on Wednesday. Stifel Nicolaus set a $46.00 target price on Zymeworks in a research report on Friday, August 7th. Finally, Citizens Jmp restated a “market outperform” rating and set a $32.00 price target on shares of Zymeworks in a research report on Wednesday. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.00.

Zymeworks Stock Performance

The business’s 50 day simple moving average is $24.73 and its 200-day simple moving average is $24.77. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -14.51 and a beta of 1.15.

Zymeworks (NASDAQ:ZYME) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). The firm had revenue of $3.23 million for the quarter, compared to analysts’ expectations of $4.54 million. Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%.The firm’s revenue for the quarter was down 90.6% on a year-over-year basis. During the same period last year, the business earned $0.03 earnings per share. Research analysts expect that Zymeworks Inc. will post 1.25 earnings per share for the current year.

Zymeworks announced that its board has approved a stock buyback program on Thursday, May 14th that allows the company to repurchase $125.00 million in shares. This repurchase authorization allows the company to purchase up to 7% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Zymeworks in the second quarter valued at approximately $508,000. California State Teachers Retirement System increased its stake in Zymeworks by 2,538.8% during the second quarter. California State Teachers Retirement System now owns 986,628 shares of the company’s stock valued at $25,790,000 after acquiring an additional 949,239 shares during the period. Nykredit A S acquired a new position in shares of Zymeworks in the second quarter valued at $25,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Zymeworks during the 2nd quarter worth about $475,000. Finally, Wellington Management Group LLP acquired a new stake in Zymeworks during the second quarter valued at approximately $2,876,000. 92.89% of the stock is owned by institutional investors.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.